🔎 Trials Near Me

Gara Jalqabaatti › Luukemiya Mayiloomonositikii Keessummaa › Massachusetts

Qorannoo klinikaalii Luukemiya Mayiloomonositikii Keessummaa Massachusetts keessatti

Qorannoo 7 Luukemiya Mayiloomonositikii Keessummaa f Massachusetts keessatti hirmaatuu jiru.

Magaalota Massachusetts keessatti

Takkalaa qorannoo (Ingiliffa)

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT04996875

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

  • Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT07249346

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Elb-2026 · NCT04256317

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 66 · Saalaa hunda · Haaromfame 17-Bit-2026 · NCT06859424

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

  • Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 16-Bit-2026 · NCT06994676

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

  • DFCI, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Gur-2026 · NCT06950034

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Elb-2025 · NCT06462365

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.